Enbrel psoriasis submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Wyeth/Amgen submit Enbrel (etanercept) supplement for treatment of moderate to severe plaque psoriasis June 30. Enbrel is the first tumor necrosis factor inhibitor to be submitted for psoriasis, Amgen said. TNF is the dominant inflammatory cytokine in the conditio